Alterations in serum MMP and TIMP concentrations following chronic heroin abuse

References

• American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders. Washington (DC): American Psychiatric Association
   Google Scholar
• Badra G, Lotfy M, El-Refaie A, et al. (2010). Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis C patients. Acta Microbiol Immunol Hung 57:29–42
   PubMedGoogle Scholar
• Boeker KH, Haberkorn CI, Michels D, et al. (2002). Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta 316:71–81
   PubMed Web of Science ®Google Scholar
• Chang PJ, Chen MY, Huang YS, et al. (2010). Morphine enhances tissue content of collagen and increases wound tensile strength. J Anesth 24:240–6
   PubMedGoogle Scholar
• Clark IM, Swingler TE, Sampieri CL, Edwards DR. (2008). The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 40:1362–78
   PubMed Web of Science ®Google Scholar
• Consolo M, Amoroso A, Spandidos DA, Mazzarino Mc. (2009). Matrix metalloproteinases and their inhibitors as markers of inflammation and fibrosis in chronic liver disease. Int J Mol Med 24:143–52
   PubMed Web of Science ®Google Scholar
• El-Gindy I, El Rahman AT, El-Alim MA, Zaki SS. (2003). Diagnostic potential of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as non-invasive markers of hepatic fibrosis in patients with HCV related chronic liver disease. Egypt J Immunol 10:27–35
   PubMedGoogle Scholar
• Gach K, Szemraj J, Wyrębska A, Janecka A. (2011). The influence of opioids on matrix metalloproteinase-2 and -9 secretion and mRNA levels in MCF-7 breast cancer cell line. Mol Biol Rep 38:1231–6
   PubMedGoogle Scholar
• Guido M, De Franceschi L, Olivari N, et al. (2006). Effects of interferon plus ribavirin treatment on NF-kappaB, TGF-beta1, and metalloproteinase activity in chronic hepatitis C. Mod Pathol 19:1047–54
   PubMedGoogle Scholar
• Harimaya Y, Koizumi K, Andoh T, et al. (2002). Potential ability of morphine to inhibit the adhesion, invasion and metastasis of metastatic colon 26-L5 carcinoma cells. Cancer Lett 187:121–7
   PubMed Web of Science ®Google Scholar
• Kampa M, Hatzoglou A, Notas G, et al. (2001). Opioids are non-competitive inhibitors of nitric oxide synthase in T47D human breast cancer cells. Cell Death Differ 8:943–52
   PubMed Web of Science ®Google Scholar
• Koulentaki M, Valatas V, Xidakis K, et al. (2002). Matrix metalloproteinases and their inhibitors in acute viral hepatitis. J Viral Hepat 9:189–93
   PubMedGoogle Scholar
• Lemjabbar H, Gosset P, Lechapt-Zalcman E, et al. (1999). Overexpression of alveolar macrophage gelatinase B (MMP-9) in patients with idiopathic pulmonary fibrosis: effects of steroid and immunosuppressive treatment. Am J Respir Cell Mol Biol 20:903–13
   PubMed Web of Science ®Google Scholar
• Leroy V, Monier F, Bottari S, et al. (2004). Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 99:271–9
   PubMed Web of Science ®Google Scholar
• Li YY, McTiernan CF, Feldman AM. (2000). Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling. Cardiovasc Res 46:214–24
   PubMed Web of Science ®Google Scholar
• Lichtinghagen R, Bahr MJ, Wehmeier M, et al. (2003). Expression and coordinated regulation of matrix metalloproteinases in chronic hepatitis C and hepatitis C virus-induced liver cirrhosis. Clin Sci (Lond) 105:373–82
   PubMed Web of Science ®Google Scholar
• Lichtinghagen R, Huegel O, Seifert T, et al. (2000). Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C. Clin Chem 46:183–92
   PubMed Web of Science ®Google Scholar
• Liu WT, Han Y, Liu YP, et al. (2010). Spinal matrix metalloproteinase-9 contributes to physical dependence on morphine in mice. J Neurosci 30:7613–23
   PubMedGoogle Scholar
• Madala SK, Pesce JT, Ramalingam TR, et al. (2010). Matrix metalloproteinase 12-deficiency augments extracellular matrix degrading metalloproteinases and attenuates IL-13-dependent fibrosis. J Immunol 184:3955–63
   PubMed Web of Science ®Google Scholar
• Mangoud AM, Sanad SM, Hendawy A, et al. (2004). Non-histological assessment of liver fibrosis in HCV infection. J Egypt Soc Parasitol 34:383–95
   PubMedGoogle Scholar
• McLellan A, Luborsky L, Cacciola J, et al. (1985). New data from the Addiction Severity Index: reliability and validity in three centers. J Nerv Ment Dis 173:412–23
   PubMed Web of Science ®Google Scholar
• Pfeilschifter J, Eberhardt W, Huwiler A. (2001). Nitric oxide and mechanisms of redox signalling: matrix and matrix-metabolizing enzymes as prime nitric oxide targets. Eur J Pharmacol 429:279–86
   PubMed Web of Science ®Google Scholar
• Robert V, Besse S, Sabri A, et al. (1997). Differential regulation of matrix metalloproteinases associated with aging and hypertension in the rat heart. Lab Invest 76:729–38
   PubMed Web of Science ®Google Scholar
• Rysz J, Banach M, Stolarek RA, et al. (2011). Serum metalloproteinases MMP-2, MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in patients on hemodialysis. Int Urol Nephrol 43:491–8
   PubMedGoogle Scholar
• Sagar S, Sorbi D, Arbeit LA, Singhal Pc. (1994). Morphine modulates 72-kDa matrix metalloproteinase. Am J Physiol 267:654–9
   Google Scholar
• Shariftabrizi A, Nifli AP, Ansari M, et al. (2006). Matrix metalloproteinase 2 secretion in WEHI 164 fibrosarcoma cells is nitric oxide-related and modified by morphine. Eur J Pharmacol 530:33–9
   PubMedGoogle Scholar
• Stetler-Stevenson W, Corcoran M, Kleiner DJ. (1996). Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol 148:1345–50
   PubMed Web of Science ®Google Scholar
• World Medical Association Inc. (2009). Declaration of Helsinki. Ethical principles for medical research involving human subjects. J Indian Med Assoc 107:403–5
   PubMedGoogle Scholar